Basic Information
Steglatro
Regulatory Information
EMEA/H/C/004315
March 21, 2018
January 25, 2018
9
November 22, 2024
Company Information
the netherlands
Waarderweg 39 2031 BN Haarlem
Merck Sharp & Dohme BV
Active Substances Detail
ertugliflozin l-pyroglutamic acid
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: - as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. - in addition to other medicinal products for the treatment of diabetes.
Overview Summary
Steglatro is a medicine used to treat adults with type 2 diabetes together with diet and exercise. Steglatro can be used in combination with other diabetes medicines or on its own in patients who cannot take metformin. Steglatro contains the active substance ertugliflozin.